- Home
- GILD vs TD Comparison
GILD vs TD Comparison
Compare GILD & TD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | TD |
|---|---|---|
| Founded | 1987 | 1855 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4B | 195.5B |
| IPO Year | 2003 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GILD | TD |
|---|---|---|
| Price | $156.45 | $124.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 14 |
| Target Price | ★ $159.85 | $119.65 |
| AVG Volume (30 Days) | ★ 4.9M | 1.4M |
| Earning Date | 10-29-2026 | 12-03-2026 |
| Dividend Yield | 2.09% | ★ 2.51% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,689,000,000.00 | N/A |
| Revenue This Year | $4.36 | $8.49 |
| Revenue Next Year | $6.88 | $5.67 |
| P/E Ratio | ★ N/A | $11.65 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $114.02 | $79.52 |
| 52 Week High | $160.51 | $125.64 |
Technical Indicators
Market Signals| Indicator | GILD | TD |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 65.89 |
| Support Level | $142.91 | $116.42 |
| Resistance Level | $158.90 | N/A |
| Average True Range (ATR) | 3.75 | 2.03 |
| MACD | 0.55 | 1.03 |
| Stochastic Oscillator | 81.19 | 94.06 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets by the end of April 2026. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 50% of its revenue from Canada and has dominant market shares in nearly all banking products and services. TD has around 44% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.